Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib +/- Toripalimab in Advanced Solid Tumors
NCT04169672Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2019
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in solid tumor (advanced stage), neuroendocrine carcinoma (NEC), sponsored by Hutchison MediPharma (HMP). Started Dec 2019; status: completed.
02
Drugs
surufatinib
03
Conditions
solid tumor (advanced stage)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04169672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169672.